OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
Manufacturers are taking the first steps toward process intensification.
This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.
September 21, 2022
Boehringer Ingelheim will use Virtuosi to train employees at three aseptic sites across its network.
September 19, 2022
Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.
September 16, 2022
The White House hopes to expand US modern biotech manufacturing and reduce reliance on foreign sources of bioindustrial materials.
Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.
September 15, 2022
Document integrity is critical in the provision of raw materials for cell and gene therapy manufacturing.
For cell and gene therapies to reach their full potential, changes in manufacturing must be explored.
September 14, 2022
MilliporeSigma’s €130 million (USD$132 million) investment is designed to increase manufacturing capacity of single-use assemblies.
September 09, 2022
Charles River Laboratories and Cure AP-4 will collaborate on gene therapy manufacturing for AP-4 hereditary spastic paraplegia.
September 06, 2022
Hovione has expanded its drug product offering with a new manufacturing line dedicated to continuous tableting.
September 02, 2022
The projected growth in the biosimilars market will require increased bulk mAb manufacturing.